Taikang Biotech's July Revenue Jumps 183.97% YoY to NT$212 Million on Royalty and CDMO Growth

July 2026 vs. July 2025: How Much Did Revenue Grow?

According to a MoneyDJ report citing Taikang Biotech's (台康生技, TWSE: 6589) monthly filing, the company's July 2026 revenue came in at NT$211,799 thousand (roughly NT$212 million), against NT$74,585 thousand in the same month of July 2025. MoneyDJ's filing data puts the year-over-year change at 183.97%. Dividing the two figures (211,799 ÷ 74,585) shows July revenue running at roughly 2.84 times the year-earlier level — consistent with the reported 183.97% growth rate.

Cumulative Revenue for the First Seven Months of 2026

MoneyDJ's filing data shows cumulative revenue for January–July 2026 at NT$832,545 thousand (about NT$832.5 million, often rounded to NT$8.33 billion... actually NT$833 million), up 70.91% from the same seven-month period a year earlier. Cnyes independently reported the identical figures — cumulative revenue of NT$8.33 billion... (NT$833 million) with a 70.91% cumulative year-over-year gain — corroborating the MoneyDJ filing data with a separate outlet.

Notably, the cumulative growth rate (70.91%) is well below the standalone July growth rate (183.97%), indicating that growth was more pronounced in July than across the first seven months as a whole.

What's Driving Taikang's Revenue Jump?

MoneyDJ's report includes a company filing note explaining the increase: "This month's and this year's revenue increased from the same period last year primarily due to the gradual recognition of licensing royalties from self-owned products and growth in the CDMO business." No further breakdown of the royalty amount or CDMO contribution was disclosed in the filing.

Monthly Growth and the Six-Month Revenue Trend

Cnyes reported that July 2026 revenue rose 86.93% month-over-month, in addition to the 183.97% year-over-year gain. Cnyes also published a six-month revenue table (February–July 2026) showing a volatile trend before July's acceleration:

The six-month table shows month-over-month swings ranging from -28% (April) to +86.93% (July), with year-over-year rates also turning negative in April (-16%) before climbing back to triple digits by June (+94%) and July (+183.97%).

Stock Price and Institutional Investor Response

Cnyes reported Taikang's latest share price at NT$48.2, up 7.47% over the preceding five trading days. Over the same five-day window, the broader biotech/healthcare sector gained 9.67% — meaning Taikang's own stock rose less than the sector average. Cnyes's own assessment characterized the stock's short-term price action as showing "no notable performance" (短期股價無明顯表現) despite the revenue report.

On the institutional side, Cnyes reported net institutional buying over the same five-day period: total institutional investors bought a net 830 lots, with foreign investors alone net-buying 871 lots, investment trusts net-flat at 0 lots, and proprietary dealers net-selling 41 lots.

What this means: the revenue figures from MoneyDJ and Cnyes are internally consistent — both report July revenue of NT$211.799 million (183.97% YoY, 86.93% MoM) and cumulative January–July revenue of NT$832.545 million (70.91% YoY). The gap between July's 183.97% YoY rate and the lower 70.91% cumulative rate points to growth concentrating later in the period, alongside the shift from April's -16% YoY reading to July's +183.97%. Yet the net foreign buying (+871 lots) and 7.47% five-day share-price gain reported by Cnyes trailed the 9.67% gain of the broader biotech sector over the same five days — a divergence between the revenue growth headline and the stock's relative market reaction that Cnyes itself flagged as unremarkable.